176 related articles for article (PubMed ID: 22741804)
1. The efficacy of conceptual DFT descriptors and docking scores on the QSAR models of HIV protease inhibitors.
Srivastava HK; Choudhury C; Sastry GN
Med Chem; 2012 Sep; 8(5):811-25. PubMed ID: 22741804
[TBL] [Abstract][Full Text] [Related]
2. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors.
Khedkar VM; Ambre PK; Verma J; Shaikh MS; Pissurlenkar RR; Coutinho EC
J Mol Model; 2010 Jul; 16(7):1251-68. PubMed ID: 20069323
[TBL] [Abstract][Full Text] [Related]
3. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
[TBL] [Abstract][Full Text] [Related]
4. QSAR studies on HIV-1 protease inhibitors using non-linearly transformed descriptors.
Saranya N; Selvaraj S
Curr Comput Aided Drug Des; 2012 Mar; 8(1):10-49. PubMed ID: 21999608
[TBL] [Abstract][Full Text] [Related]
5. QSAR prediction of HIV-1 protease inhibitory activities using docking derived molecular descriptors.
Fatemi MH; Heidari A; Gharaghani S
J Theor Biol; 2015 Mar; 369():13-22. PubMed ID: 25600056
[TBL] [Abstract][Full Text] [Related]
6. Receptor- and ligand-based study of fullerene analogues: comprehensive computational approach including quantum-chemical, QSAR and molecular docking simulations.
Ahmed L; Rasulev B; Turabekova M; Leszczynska D; Leszczynski J
Org Biomol Chem; 2013 Sep; 11(35):5798-808. PubMed ID: 23900343
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 protease inhibitors: a comparative QSAR analysis.
Kurup A; Mekapati SB; Garg R; Hansch C
Curr Med Chem; 2003 Sep; 10(17):1679-88. PubMed ID: 12871116
[TBL] [Abstract][Full Text] [Related]
8. From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors.
Bhhatarai B; Garg R
Bioorg Med Chem; 2005 Jun; 13(12):4078-84. PubMed ID: 15911321
[TBL] [Abstract][Full Text] [Related]
9. Comparative molecular field analysis (CoMFA), topomer CoMFA, and hologram QSAR studies on a series of novel HIV-1 protease inhibitors.
Heidari A; Fatemi MH
Chem Biol Drug Des; 2017 Jun; 89(6):918-931. PubMed ID: 27933723
[TBL] [Abstract][Full Text] [Related]
10. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
Halder AK; Jha T
Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
[TBL] [Abstract][Full Text] [Related]
11. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
Santos-Filho OA; Hopfinger AJ
J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
[TBL] [Abstract][Full Text] [Related]
12. Anti HIV-1 agents 6. Synthesis and anti-HIV-1 activity of indolyl glyoxamides.
Wang Y; Huang N; Yu X; Yang LM; Zhi XY; Zheng YT; Xu H
Med Chem; 2012 Sep; 8(5):831-3. PubMed ID: 22741604
[TBL] [Abstract][Full Text] [Related]
13. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
Li D; Liu MS; Ji B; Hwang KC; Huang Y
Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
[TBL] [Abstract][Full Text] [Related]
14. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
15. Development of anti-HIV activity models of lysine sulfonamide analogs: a QSAR perspective.
Muthukumaran R; Sangeetha B; Amutha R; Mathur PP
Curr Comput Aided Drug Des; 2012 Mar; 8(1):70-82. PubMed ID: 21999609
[TBL] [Abstract][Full Text] [Related]
16. Docking and multivariate methods to explore HIV-1 drug-resistance: a comparative analysis.
Almerico AM; Tutone M; Lauria A
J Comput Aided Mol Des; 2008 May; 22(5):287-97. PubMed ID: 18273557
[TBL] [Abstract][Full Text] [Related]
17. Finding the structural requirements of diverse HIV-1 protease inhibitors using multiple QSAR modelling for lead identification.
Halder AK
SAR QSAR Environ Res; 2018 Nov; 29(11):911-933. PubMed ID: 30332922
[TBL] [Abstract][Full Text] [Related]
18. Towards designing of a potential new HIV-1 protease inhibitor using QSAR study in combination with Molecular docking and Molecular dynamics simulations.
Baassi M; Moussaoui M; Soufi H; Rajkhowa S; Sharma A; Sinha S; Belaaouad S
PLoS One; 2023; 18(4):e0284539. PubMed ID: 37079533
[TBL] [Abstract][Full Text] [Related]
19. Fragment-Based QSAR and Structural Analysis of a Series of Hydroxyethylamine Derivatives as HIV-1 Protease Inhibitors.
Ferreira LG; Andricopulo AD
Comb Chem High Throughput Screen; 2015; 18(5):464-75. PubMed ID: 25961662
[TBL] [Abstract][Full Text] [Related]
20. SMILES-based optimal descriptors: QSAR analysis of fullerene-based HIV-1 PR inhibitors by means of balance of correlations.
Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
J Comput Chem; 2010 Jan; 31(2):381-92. PubMed ID: 19479738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
